title: Regional pharmacokinetic selectivity of intrapleural cisplatin.
abstract: The pharmacokinetics and toxicity of cisplatin were investigated in 3 patients affected by malignant mesothelioma who received 90 mg/m2 of the drug intrapleurally. The mean area under the pleural Pt concentration versus time curve (AUC) [12.83 (S.D. 4.06) mg.min/ml] was about 50 times greater than that detected in plasma [0.27 (0.03) mg.min/ml], indicating a clear pharmacological advantage for this route of administration. The mean plasma total Pt concentration was 1.1 micrograms/ml and the apparent total body clearance was 268 (101) ml/min. Platinum plasma pharmacokinetic data measured following intrapleural cisplatin administration (4 patients) were compared with those observed in 7 patients treated intravenously with the same dose of cisplatin (90 mg/m2) under the same modalities of hydration. Intrapleural administration of cisplatin resulted in significantly lower plasma total partial AUC (P less than 0.05) and prolonged plasma levels of filterable Pt compared with intravenous administration. No difference between the two routes of cisplatin administration in the renal clearance (S.D.) of filterable Pt [132 (64) ml/min and 122 (39) ml/min for intravenous and intrapleural cisplatin, respectively] were observed. None of the mesothelioma patients developed clinical symptoms or signs of pleural inflammation. The intrapleural treatment did not produce haemotoxicity and the emetic toxicity was lower compared with that observed in patients receiving cisplatin intravenously.
authors.affiliation: Istituto Scientifico di Medicina Interna, University of Genoa, Italy.
authors.forename: G V
authors.initials: GV
authors.lastname: Bogliolo
authors.forename: R
authors.initials: R
authors.lastname: Lerza
authors.forename: G B
authors.initials: GB
authors.lastname: Bottino
authors.forename: M P
authors.initials: MP
authors.lastname: Mencoboni
authors.forename: I M
authors.initials: IM
authors.lastname: Pannacciulli
authors.forename: M
authors.initials: M
authors.lastname: Vannozzi
authors.forename: R A
authors.initials: RA
authors.lastname: Fulco
authors.forename: F
authors.initials: F
authors.lastname: Merlo
authors.forename: M
authors.initials: M
authors.lastname: Esposito
mesh_terms: D000368:Aged; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D010984:Platinum / Q000097:blood / Q000493:pharmacokinetics; D010994:Pleura / Q000737:chemistry; D010997:Pleural Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D010984:Platinum; D002945:Cisplatin